Ergotamine tartrate

CAS 379-79-3

Interested in hearing more about this API?

Ergotamine Tartrate can cause developmental toxicity according to state or federal government labeling requirements.

About the API

Technology

Plant Extraction

Therapeutic category

Migraine

Regulations

	EU CEP
	JP DMF
	US DMF

Systematic Name

(6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;(2R,3R)-2,3-dihydroxybutanedioic acid

Disclaimers:

This material might be protected by exclusive rights such as patents and/or supplementary protection certificates or extensions in certain jurisdictions, and therefore might not be available for specific countries. TAPI will only be able to offer and supply this pharmaceutical ingredient in the countries and exclusively for uses that are exempt from infringement of such exclusive rights in accordance with applicable law. TAPI requires adequate confirmation of the exempt use upon ordering.

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources. For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.